National Bank of Canada FI Lowers Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

National Bank of Canada FI reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 94.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 387 shares of the biotechnology company's stock after selling 7,140 shares during the period. National Bank of Canada FI's holdings in Sarepta Therapeutics were worth $48,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Janus Henderson Group PLC raised its position in shares of Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Wellington Management Group LLP grew its stake in Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company's stock worth $94,148,000 after purchasing an additional 63,437 shares during the period. Thrivent Financial for Lutherans raised its holdings in Sarepta Therapeutics by 6.3% in the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company's stock worth $101,858,000 after purchasing an additional 37,940 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Sarepta Therapeutics during the third quarter valued at $79,425,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded down $5.51 on Wednesday, reaching $120.25. The stock had a trading volume of 942,689 shares, compared to its average volume of 1,217,970. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a 1 year low of $89.92 and a 1 year high of $173.25. The stock has a market cap of $11.49 billion, a P/E ratio of 96.20 and a beta of 0.77. The company has a 50 day simple moving average of $123.46 and a 200 day simple moving average of $131.44.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the company's stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company's stock, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. William Blair upgraded shares of Sarepta Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Royal Bank of Canada reiterated an "outperform" rating and set a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. Needham & Company LLC dropped their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating on the stock in a research report on Wednesday, November 27th. Finally, StockNews.com lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $178.71.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.